Editorial: Cross-reactive Immunity and COVID-19

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Dec 24

PMID 39717772

Authors

Aristo Vojdani

Ahmed Yaqinuddin

Alberto Beretta

Pedro A Reche

Affiliations

Soon will be listed here.

References

Reche P . Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines. Front Immunol. 2020; 11:586984. PMC: 7596387. DOI: 10.3389/fimmu.2020.586984. View

Wratil P, Schmacke N, Karakoc B, Dulovic A, Junker D, Becker M . Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses. Cell Rep. 2021; 37(13):110169. PMC: 8648802. DOI: 10.1016/j.celrep.2021.110169. View

Sanchez-Trincado J, Gomez-Perosanz M, Reche P . Fundamentals and Methods for T- and B-Cell Epitope Prediction. J Immunol Res. 2018; 2017:2680160. PMC: 5763123. DOI: 10.1155/2017/2680160. View

Murray S, Ansari A, Frater J, Klenerman P, Dunachie S, Barnes E . The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses. Nat Rev Immunol. 2022; 23(5):304-316. PMC: 9765363. DOI: 10.1038/s41577-022-00809-x. View

Fonte L, Ginori M, Garcia G, Hernandez Y, de Armas Y, Calderon E . Nonspecific Effects of Infant Vaccines Make Children More Resistant to Infection. Children (Basel). 2022; 9(12). PMC: 9777511. DOI: 10.3390/children9121858. View

van Regenmortel M . Specificity, polyspecificity, and heterospecificity of antibody-antigen recognition. J Mol Recognit. 2014; 27(11):627-39. DOI: 10.1002/jmr.2394. View

Vojdani A, Vojdani E, Kharrazian D . Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases. Front Immunol. 2021; 11:617089. PMC: 7873987. DOI: 10.3389/fimmu.2020.617089. View

Agrawal B . Heterologous Immunity: Role in Natural and Vaccine-Induced Resistance to Infections. Front Immunol. 2019; 10:2631. PMC: 6856678. DOI: 10.3389/fimmu.2019.02631. View

Ng K, Faulkner N, Wrobel A, Gamblin S, Kassiotis G . Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel. Semin Immunol. 2021; 55:101507. PMC: 8542444. DOI: 10.1016/j.smim.2021.101507. View

10.

Sewell A . Why must T cells be cross-reactive?. Nat Rev Immunol. 2012; 12(9):669-77. PMC: 7097784. DOI: 10.1038/nri3279. View

11.

Bodas-Pinedo A, Lafuente E, Pelaez-Prestel H, Ras-Carmona A, Subiza J, Reche P . Combining different bacteria in vaccine formulations enhances the chance for antiviral cross-reactive immunity: a detailed analysis for influenza A virus. Front Immunol. 2023; 14:1235053. PMC: 10477994. DOI: 10.3389/fimmu.2023.1235053. View

12.

Tan C, Owen C, Tham C, Bertoletti A, van Dorp L, Balloux F . Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses. Infect Genet Evol. 2021; 95:105075. PMC: 8428999. DOI: 10.1016/j.meegid.2021.105075. View

13.

Lin C, Wolf J, Brice D, Sun Y, Locke M, Cherry S . Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response. Cell Host Microbe. 2021; 30(1):83-96.e4. PMC: 8648673. DOI: 10.1016/j.chom.2021.12.005. View

14.

Ballesteros-Sanabria L, Pelaez-Prestel H, Ras-Carmona A, Reche P . Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants. Biomedicines. 2022; 10(5). PMC: 9138591. DOI: 10.3390/biomedicines10050996. View

15.

Kundu R, Narean J, Wang L, Fenn J, Pillay T, Fernandez N . Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat Commun. 2022; 13(1):80. PMC: 8748880. DOI: 10.1038/s41467-021-27674-x. View

16.

Vojdani A, Vojdani E, Melgar A, Redd J . Reaction of SARS-CoV-2 antibodies with other pathogens, vaccines, and food antigens. Front Immunol. 2022; 13:1003094. PMC: 9537454. DOI: 10.3389/fimmu.2022.1003094. View

17.

Eggenhuizen P, Ng B, Chang J, Cheong R, Yellapragada A, Wong W . Heterologous Immunity Between SARS-CoV-2 and Pathogenic Bacteria. Front Immunol. 2022; 13:821595. PMC: 8829141. DOI: 10.3389/fimmu.2022.821595. View

18.

Sharma S, Thomas P . The two faces of heterologous immunity: protection or immunopathology. J Leukoc Biol. 2013; 95(3):405-16. PMC: 3923083. DOI: 10.1189/jlb.0713386. View